Bacteriophage ΦCJ20 Antibacterial Composition for ETEC Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preventing and treating infectious diseases caused by enterotoxigenic Escherichia coli (ETEC) in animals are inadequate, particularly in the pork industry, where antibiotic misuse has led to drug resistance and economic losses, and existing bacteriophages do not effectively target ETEC.

Innovation Solution

Development of a novel bacteriophage ΦCJ20 (KCCM11362P) with specific bactericidal activity against ETEC, which is resistant to acid and heat, and its use in compositions such as antibiotics, feed additives, disinfectants, and cleaners to prevent and treat ETEC infections in animals.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to prevent and treat ETEC infections, then treatment effectiveness is improved, but drug resistance develops and antibiotic residues remain in animal bodies

Engineering Contradiction:

Improvetreatment effectivenessVSAvoiddrug resistance and antibiotic residues

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses bacteriophage ΦCJ20 as an intermediary agent to treat ETEC infections. Instead of directly applying antibiotics that cause resistance, the bacteriophage acts as a mediator that specifically infects and lyses ETEC bacteria through its lytic cycle, eliminating the pathogen without inducing drug resistance or leaving harmful residues in animal bodies

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the chemical mechanism of antibiotics with a biological mechanism using bacteriophage. The bacteriophage utilizes its natural infection and lysis cycle to kill ETEC bacteria, substituting the chemical action of antibiotics with a biological process that is self-limiting and does not create resistance in the same way antibiotics do

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If existing bacteriophages are used to control E. coli, then bacterial infection is reduced, but they do not effectively target ETEC specifically

Engineering Contradiction:

Improvebacterial infection controlVSAvoidhost specificity for ETEC

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies the principle of local quality by engineering or selecting a bacteriophage with highly specific host recognition properties tailored to ETEC. The bacteriophage ΦCJ20 has specific receptor-binding proteins that recognize and bind to unique surface structures on ETEC, providing localized and specific action against this pathogen while leaving other bacteria unaffected

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes in the bacteriophage's host range characteristics. By modifying or selecting for specific genetic parameters in the bacteriophage that determine host specificity, the patent creates a strain that is highly adapted to infect ETEC while maintaining the ability to self-replicate and lyse the target bacteria effectively

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The bacteriophage ΦCJ20 effectively kills ETEC, providing a resistant and targeted solution for preventing and treating ETEC infections across various temperature and pH ranges, reducing the need for antibiotics and minimizing drug resistance.

Implementation Method 1

a novel bacteriophage ΦCJ20 (KCCM11362P) having a specific bactericidal activity against enterotoxigenic Escherichia coli (ETEC)

Methodology Applied

Scientific EffectBacteriophage lytic activity:

Implementation Method 2

The bacteriophage has strong host specificity as compared to antibiotics, and recently, a problem of emergence of strain resistant against antibiotics has been serious

Methodology Applied

Scientific EffectBactericidal activity:

Implementation Method 3

which is resistant to acid and heat

Methodology Applied

Scientific EffectAcid resistance:

Implementation Method 4

which is resistant to acid and heat

Methodology Applied

Scientific EffectHeat resistance:

Data Source

PatentUS9862935B2Bacteriophage and antibacterial composition comprising the same

Publication Date: 2018.01.09 CJ CHEILJEDANG CORP

AI summary

Provided is a novel bacteriophage ΦCJ20 (KCCM11362P). In addition, the present invention relates to an antibacterial composition including the bacteriophage ΦCJ20 (KCCM11362P) as an active ingredient. Further, the present invention is a method of preventing and/or treating infectious diseases by enterotoxigenic Escherichia coli in animals except for humans using the bacteriophage ΦCJ20 (KCCM11362P) or the antibacterial composition containing the bacteriophage ΦCJ20 (KCCM11362P) as an active ingredient.